Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.50 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.50 |
| ▸ | PHF8 | Q9UPP1 | 7/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 7/20 | 0.46 |
| ▸ | KDM5C | P41229 | 5/20 | 0.46 |
| ▸ | KDM6B | O15054 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1992862 | 0.91 | LMNA (0.60) | EGLN1LMNAALKBH5SUCNR1PHF8 | |
| SCHEMBL288701 | 0.91 | LMNA (0.60) | EGLN1LMNAALKBH5SUCNR1PHF8 | |
| SCHEMBL2218408 | 0.88 | LMNA (0.56) | EGLN1LMNAALKBH5SUCNR1PHF8 | |
| Ammonia Solution, Strong SCHEMBL28163791 | 0.88 | LMNA (0.56) | EGLN1LMNAALKBH5SUCNR1PHF8 | |
| SCHEMBL27749051 | 0.88 | LMNA (0.56) | EGLN1LMNAALKBH5SUCNR1PHF8 | |
| SCHEMBL27705671 | 0.88 | LMNA (0.56) | EGLN1LMNAALKBH5SUCNR1PHF8 | |
| SCHEMBL812816 | 0.86 | ALDH1A1 (0.46) | EGLN1LMNAALKBH5SUCNR1PHF8 | |
| SCHEMBL21295465 | 0.85 | EGLN1 (0.50) | EGLN1LMNAALKBH5SUCNR1PHF8 | |
| SCHEMBL8382882 | 0.85 | PHF8 (0.54) | EGLN1LMNAALKBH5SUCNR1PHF8 | |
| SCHEMBL429060 | 0.83 | LMNA (0.53) | EGLN1LMNAALKBH5SUCNR1PHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10974498-B2 | Additive fabrication process with a structural material comprising an IR absorber | COVESTRO DEUTSCHLAND AG (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20190344555-A1 | ADDITIVE FABRICATION PROCESS WITH A STRUCTURAL MATERIAL COMPRISING AN IR ABSORBER | COVESTRO DEUTSCHLAND AG (DE) | 2019-11-14 | — | — | US | disclosed |
| US-7217708-B2 | Cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-05-15 | — | — | US | disclosed |
| EP-1389213-B1 | 3,7-DIAZABICYCLO 3.3.1| FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1550663-A1 | New crystalline forms of antiarrhythmic compounds | Astra Zeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| US-20040143000-A1 | 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | US | disclosed |
| EP-1389213-A1 | 3,7-DIAZABICYCLO 3.3.1] FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | AstraZeneca AB (SE) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002083688-A1 | 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| US-5541305-A | PREPARED BY ION EXCHANGE COMPLEXATION OF POLYMER HAVING QUATERNARY AMMONIUM GROUPS WITH ALKALI METAL SALT OF HEPARIN OR ANALOG THEREOF | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1996-07-30 | — | — | US | disclosed |
| US-4692549-A | Carboalkoxylation of butadiene to form dialkyl adipate | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-09-08 | — | — | US | disclosed |
| EP-0015673-B1 | 3-AMINO-4-HOMOISOTWISTANE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143000-A1 | 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds | SCN3A, KCNH1, CACNA1G | EGLN1 1765/4885LMNA 807/4885ALKBH5 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.